Efficacy and Safety Evaluation of Belimumab in Treatment of Systemic Lupus Erythematosus- A Mini-review

Systemic Lupus Erythematosus (SLE) is a fairly common and widespread condition. Currently, it is clinically relevant in most healthcare facilities and is discussed in both the medical and scientific literature. There is a wealth of data from both clinicians and researchers studying the problems and treatment options associated with SLE. Systemic lupus erythematosus is characterized by clinical variability, irregular course, and relapses (SLE). Although SLE is primarily a systemic autoimmune disease, it can sometimes be organ-specific, creating diagnostic difficulties. B-cell activating factor (BAFF) is attacked by belimumab (a monoclonal antibody), which reduces the level of BLys (B-lymphocyte stimulating cell), which is a chief cytokine in the pathophysiology of SLE. In our review of the literature, we tried to determine the efficacy and safety of the drug belimumab in the context of patients with SLE and how it affects their recovery and management. We have reviewed the two studies which were conducted regarding the role of this drug which was found to be promising and beneficial for seeking a new treatment route for the clinicians. Also, we have described different domains of the study and their mathematical results regarding the efficacy of the drug henceforth. We seek to describe the safest use and the best possible results that clinicians can achieve when treating patients with SLE, and we provide high levels of clinical care at the highest level. We advise physicians to monitor all areas of the drug's activity and to make educated and informed judgments, which are principally discussed in our article.